Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Inclusion Criteria:

1. Angiographically documented active choroidal neovascular (CNV) lesion (i.e., leakageon fluorescein angiography or subretinal, intraretinal, or sub-retinal pigmentepithelium [sub-RPE] fluid on spectral domain optical coherence tomography [SD-OCT])secondary to age-related macular degeneration (AMD), within the previous 10 weeks

2. Subjects must have received, 7 to 14 days prior to the Baseline Visit, anintravitreal injection in the study eye of an anti-vascular endothelial growthfactor (VEGF) ocular therapeutic approved for use in the United States

Exclusion Criteria:

1. History or current evidence of a medical condition (systemic or ophthalmic disease,metabolic dysfunction, physical examination finding or clinical laboratory finding)that may, in the opinion of the investigator, preclude the safe administration ofthe study medication, adherence to the scheduled study visits, or safe participationin the study or affect the results of the study (e.g., unstable or progressivecardiovascular, cerebral vascular, pulmonary, Parkinson's, liver or renal disease,depression, cancer, or dementia)

2. History or evidence of the following surgeries/procedures in the study eye:

3. Submacular surgery

4. Vitrectomy

5. Retinal detachment or retinal tear

6. Incisional glaucoma surgery